Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- And high-grade ovarian serous carcinomas

Chinese Journal of Pathology

Volumn 40, Issue 8, 2011, Pages 511-516

  Shen, Xu Xia ^a,b   Yu, Lin ^a,b   Bi, Rui ^a,b   Yang, Wen Tao ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Immunohistochemistry; Neoplasm staging; Ovarian neoplasms; Prognosis

Indexed keywords

CA 125 ANTIGEN; KI 67 ANTIGEN; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN; PAX2 PROTEIN, HUMAN; PROTEIN P53; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR PAX2;

ARTICLE; CANCER GRADING; CANCER STAGING; CLASSIFICATION; CYSTADENOCARCINOMA; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MORTALITY; OVARY; OVARY TUMOR; PATHOLOGY; SURVIVAL RATE;

CA-125 ANTIGEN; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARY; PAX2 TRANSCRIPTION FACTOR; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80052478244     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2011.08.003     Document Type: Article

References (22)

1. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposaL Int J Gynecol Pathol, 2000, 19(1) : 7-15.
2. Singer G., Kurman R.J., Chang H.W., el al. Diverse tumorigenic pathways in ovarian serous carcinoma. AmJ Pathol, 2002, 160 (4) : 1223-1228. (Pubitemid 34411626)
3. Malpica A., Deavers M.T., Lu K., et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol, 2004, 28 (4) : 496-504. (Pubitemid 38436523)
4. Shih IeM, Kurman R.J. Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Pathol, 2004, 164(5): 1511-1518. (Pubitemid 38529752)
5. Tong G.X., Chiriboga L., Hamele-Bena D., et al. Expression of PAX2 in papillary serous carcinoma of the ovary: Immunohislochemical evidence of fallopian tube or secondary Miillerian system origin? Mod Pathol, 2007, 20(8) : 856-863. (Pubitemid 47077268)
6. O'Neill C.J., Deavers M.T., Malpica A., et al. An immunohistochemical comparison between low-grade and highgrade ovarian serous carcinomas: Significantly higher expression of p53, MIBl, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol, 2005, 29(8) : 1034-1041. (Pubitemid 41045547)
7. Armstrong D.K. Relapsed ovarian cancer: Challenges and management strategies for a chronic disease. Oncologist, 2002, 7 (Suppl5): 20-28.
8. Seidman J.D., Horkayne-Szakaly I., CosinJA, et aL Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum. Gynecol Oncol, 2006, 103(2) : 703-708.
9. Vang R., Shih IeM, Kurman R.J. Ovarian low-grade and highgrade serous carcinoma; pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol, 2009, 16(5): 267-282.
10. Ayhan A., Kurman R.J., Yemelyanova A, et aL Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. Am J Surg Pathol, 2009, 33(8); 1220-1224.
11. Bortek J., Bártkovň J., Vojtěsek B., et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene, 1991,6(9); 1699-1703. (Pubitemid 21924277)
12. Chan W.Y., Cheung K.K., Schorge JO, et aL Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol, 2000, 156(2) : 409417.
13. Diebold J., Baretton G., Felchner M., et al. Bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol, 1996, 105(3); 341-349. (Pubitemid 26077376)
14. Singer G., Stöhr R., Cope L., et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis; a mutational analysis with immunohistochemical correlation. Am J Surg Pathol, 2005, 29(2); 218-224. (Pubitemid 40170640)
15. Torres M., Gómez-Pardo E., Dressier G.R., et al. Pax-2 controls multiple steps of urogenital development. Development, 1995, 121(12); 40574065.
16. Tung C.S., Mok S.C., Tsang Y.T., et al. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol, 2009, 22(9) : 1243-1250.
17. Gnarra J.R., Dressier G.R. Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides. Cancer Res, 1995, 55(18); 40924098.
18. Muratovska A., Zhou C., He S., et al. Paired-Box genes are frequently expressed in cancer and often required for cancer cell survivaL Oncogene, 2003, 22(39); 7989-7997.
19. Hueber P.A., Waters P., Clark P., et al. PAX2 inactivalion enhances cisplatin-induced apoptosis in renal carcinoma cells. Kidney Int, 2006, 69(7); 1139-1145.
20. Schmeler K.M., Sun C.C., Bodurka D.C., el al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol, 2008, 108(3) : 510-514.
21. Gershenson D.M., Sun C.C., Lu K.H., et al. Clinical behavior of stage U-IV low-grade serous carcinoma of the ovary. Obstet Gynecol, 2006, 108(2) : 361-368. (Pubitemid 44305678)
22. Malpica A., Deavers M.T., Tomos C., et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol, 2007, 31(8) : 1168-1174. (Pubitemid 47207118)